Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101319 | 0.74 | CXCR4 (0.48) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL31875233 | 0.74 | CACNA1H (0.44) | HTR6KDM4C | |
| SCHEMBL4072911 | 0.74 | CACNA1H (0.44) | HTR6KDM4C | |
| SCHEMBL24823072 | 0.74 | LATS1 (0.41) | CHRM2ALDH1A1 | |
| SCHEMBL18661236 | 0.73 | CXCR4 (0.42) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Hydrochloric Acid SCHEMBL27147079 | 0.73 | CACNA1H (0.42) | HTR6KDM4C | |
| SCHEMBL14131084 | 0.72 | CXCR4 (0.82) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL30096651 | 0.72 | CXCR4 (0.82) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL29733134 | 0.72 | MAPT (0.48) | CXCR4CYP2D6TDP1BCHEALDH1A1 | |
| SCHEMBL23336458 | 0.72 | BCHE (0.66) | TDP1BCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.